BAFF and MyD88 signals promote a lupuslike disease independent of T cells

Journal of Experimental Medicine

Volumn 204, Issue 8, 2007, Pages 1959-1971

  Groom, Joanna R ^a   Fletcher, Carrie A ^a   Walters, Stacey N ^a   Grey, Shane T ^a   Watt, Sally V ^b   Sweet, Mathew J ^c   Smyth, Mark J ^b   Mackay, Charles R ^a   Mackay, Fabienne ^a  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; B CELL ACTIVATING FACTOR OF TUMOR NECROSIS FACTOR FAMILY; CYTOKINE; MYELOID DIFFERENTIATION FACTOR 88; RECEPTOR; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TRANSMEMBRANE ACTIVATOR AND CALCIUM MODULATOR AND CYCLOPHILIN LIGAND INTERACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CONTROLLED STUDY; HUMORAL IMMUNITY; LUPUS LIKE SYNDROME; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; UPREGULATION;

ANIMALS; AUTOANTIBODIES; B-CELL ACTIVATING FACTOR; CELL DIFFERENTIATION; CELL SEPARATION; GENE EXPRESSION REGULATION; IMMUNOGLOBULIN A; IMMUNOGLOBULIN M; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MODELS, BIOLOGICAL; MYELOID DIFFERENTIATION FACTOR 88; T-LYMPHOCYTES;

EID: 34547772125     PISSN: 00221007     EISSN: 00221007     Source Type: Journal    
DOI: 10.1084/jem.20062567     Document Type: Article

References (70)

1. Mills, J.A. 1994. Systemic Lupus Erythematosus. N. Engl. J. Med. 330:1871-1879.
2. Kang, I., and J. Craft. 2006. Systemic lupus erythematosus: immunological features. In The Autoimmune Diseases. Fourth edition. N.R. Rose and I.R. Mackay, editors. Elsevier Academic Press Publication. 357-368 pp
3. Davidson, A., and C. Aranow. 2006. Pathogenesis and treatment of systemic lupus erythematosus nephritis. Curr. Opin. Rheumatol. 18:468-475.
4. Isenberg, D., and A. Rahman. 2005. Systemic lupus erythematosus-2005 annus mirabillis. Nat. Clin. Pract. Rheumatol. 2:145-152.
5. Mackay, F., P. Schneider, P. Rennert, and J.L. Browning. 2003. BAFF and APRIL: a tutorial on B cell survival. Annu. Rev. Immunol. 21:231-264.
6. Carroll, M.C. 2004. A protective role for innate immunity in systemic lupus erythematosus. Nat. Rev. Immunol. 4:825-831.
7. McGaha, T.L., B. Sorrentino, and J.V. Ravetch. 2005. Restoration of tolerance in lupus by targeted inhibitory receptor expression. Science. 307:590-593.
8. Marshak-Rothstein, A. 2006. Toll-like receptors in systemic autoimmune disease. Nat. Rev. Immunol. 6:823-835.
9. Rahman, A.H., and R.A. Eisenberg. 2006. The role of toll-like receptors in systemic lupus erythematosus. Springer Semin. Immunopathol. 28:131-143.
10. Hoffman, R.W. 2004. T cells in the pathogenesis of systemic lupus erythematosus. Clin. Immunol. 113:4-13.
11. Singh, R.R. 2005. SLE: translating lessons from model systems to human disease. Trends Immunol. 26:572-579.
12. Davidson, A., X. Wang, M. Mihara, M. Ramanujam, W. Huang, L. Schiffer, and J. Sinha. 2003. Co-stimulatory blockade in the treatment of murine systemic lupus erythematosus (SLE). Ann. N. Y. Acad. Sci. 987:188-198.
13. Kalled, S.L., A.H. Cutler, S.K. Datta, and D.W. Thomas. 1998. Anti-CD40 ligand antibody treatment of SNF1 mice with established nephritis: preservation of kidney function. J. Immunol. 160:2158-2165.
14. Vinuesa, C.G., M.C. Cook, C. Angelucci, V. Athanasopoulos, L. Rui, K.M. Hill, D. Yu, H. Domaschenz, B. Whittle, T. Lambe, et al. 2005. A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity. Nature. 435:452-458.
15. Thatayatikom, A., and A.J. White. 2006. Rituximab: a promising therapy in systemic lupus erythematosus. Autoimmun. Rev. 5:18-24.
16. Vinuesa, C.G., S.G. Tangye, B. Moser, and C.R. Mackay. 2005. Follicular B helper T cells in antibody responses and autoimmunity. Nat. Rev. Immunol. 5:853-865.
17. Mackay, F., and S.G. Tangye. 2004. The role of the BAFF/APRIL system in B cell homeostasis and lymphoid cancers. Curr. Opin. Pharmacol. 4:347-354.
18. Mackay, F., F. Sierro, S.T. Grey, and T.P. Gordon. 2005. The BAFF/APRIL system: an important player in systemic rheumatic diseases. Curr. Dir. Autoimmun. 8:243-265.
19. Mackay, F., S.A. Woodcock, P. Lawton, C. Ambrose, M. Baetscher, P. Schneider, J. Tschopp, and J.L. Browning. 1999. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J. Exp. Med. 190:1697-1710.
20. Groom, J., S.L. Kalled, A.H. Cutler, C. Olson, S.A. Woodcock, P. Schneider, J. Tschopp, T.G. Cachero, M. Batten, J. Wheway, et al. 2002. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome. J. Clin. Invest. 109:59-68.
21. Batten, M., J. Groom, T.G. Cachero, F. Qian, P. Schneider, J. Tschopp, J.L. Browning, and F. Mackay. 2000. BAFF mediates survival of peripheral immature B lymphocytes. J. Exp. Med. 192:1453-1465.
22. Batten, M., C. Fletcher, L. Ng, J. Groom, J. Wheway, Y. Laâbi, X. Xin, P. Schneider, J. Tschopp, C.R. Mackay, and F. Mackay. 2004. TNF deficiency fails to protect BAFF transgenic mice against autoimmunity and reveals a predisposition to B cell lymphomas. J. Immunol. 172:812-822.
23. Fletcher, C.A., A.P. Sutherland, J.R. Groom, M.L. Batten, L.G. Ng, J. Gommerman, and F. Mackay. 2006. Development of nephritis but not sialadenitis in autoimmune-prone BAFF transgenic mice lacking marginal zone B cells. Eur. J. Immunol. 36:2504-2514.
24. Thien, M., T.G. Phan, S. Gardam, M. Amesbury, A. Basten, F. Mackay, and R. Brink. 2004. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity. 20:785-798.
25. Ng, L.G., A. Sutherland, R. Newton, F. Qian, T.G. Cachero, M.L. Scott, J.S. Thompson, J. Wheway, T. Chtanova, J. Groom, et al. 2004. BAFF-R is the principal BAFF receptor facilitating BAFF co-stimulation of B and T cells. J. Immunol. 173:807-817.
26. Sutherland, A.P., L.G. Ng, C.A. Fletcher, B. Shum, R.A. Newton, S.T. Grey, M.S. Rolph, F. Mackay, and C.R. Mackay. 2005. BAFF augments certain Th1-associated inflammatory responses. J. Immunol. 174:5537-5544.
27. Mombaerts, P., E. Mizoguchi, M.J. Grusby, L.H. Glimcher, A.K. Bhan, and S. Tonegawa. 1993. Spontaneous development of inflammatory bowel disease in T cell receptor mutant mice. Cell. 75:274-282.
28. Khare, S.D., and H. Hsu. 2001. The role of TALL-1 and APRIL in immune regulation. Trends Immunol. 22:61-63.
29. Litinskiy, M., B. Nardelli, B.M. Hilbert, H. Bing, A. Schaffer, P. Casali, and A. Cerutti. 2002. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat. Immunol. 3:822-829.
30. Castigli, E., S.A. Wilson, S. Scott, F. Dedeoglu, S. Xu, K.P. Lam, R.J. Bram, H. Jabara, and R.S. Geha. 2005. TACI and BAFF-R mediate isotype switching in B cells. J. Exp. Med. 201:35-39.
31. Schneider, P., F. Mackay, V. Steiner, K. Hofmann, J.L. Bodmer, N. Holler, C. Ambrose, P. Lawton, S. Bixler, H. Acha-Orbea, et al. 1999. BAFF, a novel ligand of the tumor necrosis factor (TNF) family, stimulates B-cell growth. J. Exp. Med. 189:1747-1756.
32. Gray, D., K. Siepmann, and G. Wohlleben. 1994. CD40 ligation in B cell activation, isotype switching and memory development. Semin. Immunol. 6:303-310.
33. Deshmukh, U.S., H. Bagavant, and S.M. Fu. 2006. Role of anti-DNA antibodies in the pathogenesis of lupus nephritis. Autoimmun. Rev. 5:414-418.
34. Hoffman, I.E., I. Peene, L. Meheus, T.W. Huizinga, L. Cebecauer, D. Isenberg, K. De Bosschere, F. Hulstaert, E.M. Veys, and F. De Keyser. 2004. Specific antinuclear antibodies are associated with clinical features in systemic lupus erythematosus. Ann. Rheum. Dis. 63:1155-1158.
35. Ehlers, M., H. Fukuyama, T.L. McGaha, A. Aderem, and J.V. Ravetch. 2006. TLR9/MyD88 signalling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. J. Exp. Med. 203:553-561.
36. Peng, S.L., S.J. Szabo, and L.H. Glimcher. 2002. T-bet regulates IgG class switching and pathogenic autoantibody production. Proc. Natl. Acad. Sci. USA. 99:5545-5550.
37. Jacob, C.O., L. Pricop, C. Putterman, M.N. Koss, Y. Liu, M. Kollaros, S.A. Bixler, C.M. Ambrose, M.L. Scott, and W. Stohl. 2006. Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand mixed 2328 mice deficient in BAFF. J. Immunol. 177:2671-2680.
38. Fukuyama, H., F. Nimmerjahn, and J.V. Ravetch. 2005. The inhibitory Fcgamma receptor modulates autoimmunity by limiting the accumulation of immunoglobulin G+ anti-DNA plasma cells. Nat. Immunol. 6:99-106.
39. Martin, R.M., and A.M. Lew. 1998. Is IgG2a a good Th1 marker in mice? Immunol. Today. 19:49.
40. Muro, Y. 2005. Antinuclear antibodies. Autoimmunity. 38:3-9.
41. Bao, L., I. Osawe, M. Haas, and R.J. Quigg. 2005. Signalling through up-regulated C3a receptor is key to the development of experimental lupus nephritis. J. Immunol. 175:1947-1955.
42. Viau, M., and M. Zouali. 2005. B-lymphocytes, innate immunity, and autoimmunity. Clin. Immunol. 114:17-26.
43. Ng, L.G., C.H. Ng, B. Woehl, A.P. Sutherland, J. Huo, S. Xu, F. Mackay, and K.P. Lam. 2006. BAFF costimulation of Toll-like receptor-activated B-1 cells. Eur. J. Immunol. 36:1837-1846.
44. Brummel, R., and P. Lenert. 2005. Activation of marginal zone B cells from lupus mice with type A(D) CpG-oligodeoxynucleotides. J. Immunol. 174:2429-2434.
45. He, B., X. Qiao, and A. Cerutti. 2004. CpG DNA induces IgG class switch DNA recombination by activating human B cells through innate pathways that require TLR9 and cooperates with IL-10. J. Immunol. 173:4479-4491.
46. Berland, R., L. Fernandez, E. Kari, J.H. Han, I. Lomakin, S. Akira, H.H. Wortis, J.F. Kearney, A.A. Ucci, and T. Imanishi-Kari. 2006. Toll-like receptor 7-dependent loss of B cell tolerance in pathogenic autoantibody knockin mice. Immunity. 25:429-440.
47. Christensen, S.R., J. Shupe, K. Nickerson, M. Kashgarian, R.A. Flavell, and M.J. Shlomchik. 2006. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity. 25:417-428.
48. Acosta-Rodriguez, E.V., A. Craxton, D.W. Hendricks, M.C. Merino, C.L. Montes, E.A. Clark, and A. Gruppi. 2007. BAFF and LPS cooperate to induce B cells to become susceptible to CD95/Fas-mediated cell death. Eur. J. Immunol. 37:990-1000.
49. von Bulow, G.-U., J.M. van Deursen, and R.J. Bram. 2001. Regulation of the T-independent humoral response by TACI. Immunity. 14:573-582.
50. Enzler, T., G. Bonizzi, G.J. Silverman, D.C. Otero, G.F. Widhopf, A. Anzelon-Mills, R.C. Rickert, and M. Karin. 2006. Alternative and classical NF-kappa B signalling retain autoreactive B cells in the splenic marginal zone and result in lupus-like disease. Immunity. 25:403-415.
51. West, A.P., A.A. Koblansky, and S. Ghosh. 2006. Recognition and signalling by Toll-like receptors. Annu. Rev. Cell Dev. Biol. 22:409-437.
52. Adachi, O., T. Kawai, K. Takeda, M. Matsumoto, H. Tsutsui, M. Sakagami, K. Nakanishi, and S. Akira. 1998. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity. 9:143-150.
53. Schmitz, J., A. Owyang, E. Oldham, Y. Song, E. Murphy, T.K. McClanahan, G. Zurawski, M. Moshrefi, J. Qin, X. Li, et al. 2005. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 23:479-490.
54. Gavin, A.L., K. Hoebe, B. Duong, T. Ota, C. Martin, B. Beutler, and D. Nemazee. 2006. Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science. 314:1936-1938.
55. Gorelik, L., A.H. Cutler, G. Thill, S.D. Miklasz, D.E. Shea, C. Ambrose, S.A. Bixler, L. Su, M.L. Scott, and S.L. Kalled. 2004. BAFF regulates CD21/35 and CD23 expression independently of its B cell survival function. J. Immunol. 172:762-766.
56. Banchereau, J., and V. Pascual. 2006. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity. 25:383-392.
57. Means, T.K., and A.D. Luster. 2005. Toll-like receptor activation in the pathogenesis of systemic lupus erythematosus. Ann. N. Y. Acad. Sci. 1062:242-251.
58. Grammer, A.C., and P.E. Lipsky. 2003. B cell abnormalities in systemic lupus erythematosus. Arthritis Res. Ther. 5:S22-S27.
59. Kaminski, D.A., and J. Stavnezer. 2006. Enhanced IgA class switching in marginal zone and B1 B cells relative to follicular/B2 B cells. J. Immunol. 177:6025-6029.
60. Ettinger, R., G.P. Sims, R. Robbins, D. Withers, R.T. Fischer, A.C. Grammer, S. Kuchen, and P.E. Lipsky. 2007. IL-21 and BAFF/BLyS synergize in stimulating plasma cell differentiation from a unique population of human splenic memory B cells. J. Immunol. 178:2872-2882.
61. Hondowicz, B.D., S.T. Alexander, W.J. Quinn III, A.J. Pagan, M.H. Metzgar, M.P. Cancro, and J. Erikson. 2007. The role of BLyS/BLyS receptors in anti-chromatin B cell regulation. Int. Immunol. 19:465-475.
62. Christensen, S.R., M. Kashgarian, L. Alexopoulou, R.A. Flavell, S. Akira, and M.J. Shlomchik. 2005. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J. Exp. Med. 202:321-331.
63. Lenert, P., R. Brummel, E.H. Field, and R.F. Ashman. 2006. TLR-9 activation of marginal zone B cells in lupus mice regulates immunity through increased IL-10 production. J. Clin. Immunol. 25:29-40.
64. Nijnik, A., H. Ferry, G. Lewis, E. Rapsomaniki, J.C. Leung, A. Daser, T. Lambe, C.C. Goodnow, and R.J. Cornall. 2006. Spontaneous B cell hyperactivity in autoimmune-prone MRL mice. Int. Immunol. 18:1127-1137.
65. Ju, Z.L., G.Y. Shi, J.X. Zuo, and J.W. Zhang. 2007. Unexpected development of autoimmunity in BAFF-R-mutant MRL-lpr mice. Immunology. 120:281-289.
66. Calvani, N., M. Tucci, H.B. Richards, P. Tartaglia, and F. Silvestris. 2005. Th1 cytokines in the pathogenesis of lupus nephritis: the role of IL-18. Autoimmun. Rev. 4:542-548.
67. Durum, S.K., J.A. Schmidt, and J.J. Oppenheim. 1985. Interleukin-1: an immunological perspective. Annu. Rev. Immunol. 3:263-287.
68. Ostendorf, B., C. Iking-Konert, K. Kurz, G. Jung, O. Sander, and M. Schneider. 2005. Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis. Ann. Rheum. Dis. 64:630-633.
69. Goodnow, C.C. 2006. Discriminating microbe from self suffers a double toll. Science. 312:1606-1608.
70. Pisitkun, P., J.A. Deane, M.J. Difilippantonio, T. Tarasenko, A.B. Satterhwaite, and S. Bolland. 2006. RNA-related antigens due to TLR7 gene duplication. Science. 312:1669-1672.